Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Robert Saylors Iii

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPeds Pediatrics, College of Medicine
DivisionPeds Hematology
Address ACH Sturgis Building
2601 Gene George Blvd.
Mail Slot # 512-10
Springdale AR 72762
Phone501-364-1494
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01CA109821     (CHAMBERS, TIMOTHY C.)Aug 1, 2004 - May 31, 2016
    NIH
    Bcl-2 Proteins in Mechanism of Anti-mitotic Drug Action
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Morrow RW, Frazier EA, Mahle WT, Harville TO, Pye SE, Saylors RL, Garcia X, Jaquiss RDB, Woodle ES. Rapid reduction in donor specific anti-HLA antibodies (DSA) and reversal of antibody mediated rejection (AMR) with bortezomib in pediatric heart transplant patients. Transplantation. 2012; 93:319-324.
    2. Watkins B, Saylors R, Saccente S, Tang X. Comparison of erythrocytapheresis and simple transfusion for the treatment of children with sickle cell acute chest syndrome. Annual Meeting of the American Society of Hematology. 2012.
    3. Cheek N, Saylors R, Ramakrishnaiah R, Saccente S, Tang X, Luo C. A single institution study of chronic erythrocytapheresis for secondary stroke prevention in children and young adults with sickle cell disease. Annual Meeting of the American Society of Hematology. 2012.
    4. Ataga KI, Reid M, Et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind, study of the Gardos channel blocker senicapoc (CA-17043). Br J Haematol. 2011; 153:92-104.
    5. Morrow W, Frazier EA, Mahle WT, Harville OT, Pye S, Saylors RL, Garcia X, Jaquiss RDB. Rapid reduction in donor specific antibodies with bortezomib in pediatric heart transplant recipients with positive crossmatch and antibody mediated rejection. The Journal Of Heart and Lung Transplantation. 2010; S87.
    6. Mian A, Becton D, Fiser R, James L, Saccente S, Saylors R, Stine K, Melguizo M. C-reactive protein and soluble IL-2 receptor correlate with high risk of clinical sepsis among children with fever and neutropenia. Blood. 2010; 114: Abstract 1406.
    7. Burns S, Saylors R, Mian A. Macrophage activation syndrome in a child with Ehrlichia chaffeensis infection. Annual Meeting of the Southern Society for Pediatric Research. 2008.
    8. Ding Y, Saylors iii RL, Brown H, Parham DY. Pulmonary inflammatory pseudotumor with HHV-8. Am. J. Surg. Path. 2002; 26:1089-1092.
    9. Saylors iii RL, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, Et al. Cyclophosphamide and topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group Phase II Study. J Clin Oncol. 2001; 19:3463-69.
    10. McMasters R, Wilbert T, Jones K, Pitylk K, Saylors iii RL, Moyer M, Chambers T, Drake R. Two-drug combinations that increase apoptosis and modulate bak anbd bcl-X(L) expression in human colon tumor lines transfected with herpes simplex virus thymidine kinase. Cancer Gene Therapy. 2000; 7:563-573.
    11. Stine KC, Saylors iii RL, Becton DL. 2-chlorodeoxyadenosine for the treatment of refractory or recurrent Langerhan's cell histiocytosis (LCH) in pediatric patients. 1999; 21:329.
    12. OBrien CA, Gubrij I, Lin SC, Saylors iii RL, Manolagas SC. STAT3 activation in stromal/osteoblastic cells is required for induction of RANKL and stimulation of osteoclastogenesis by gp-130-utilizing cytokines or IL-1, but not 1,25 (OH)2D3 or PTH. J Biol Chem. 1999; 274:19301-08.
    13. Saylors iii RL, Stine KC, Sullivan J. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group (POG) phase II study. 1999; 21:332.
    14. Ding L, Lu S, Batchu RB, Saylors iii RL, Munshi NC. Bone marrow stromal cells as a vehicle for gene transfer. Gene Ther. 1999; 6:1611-16.
    15. Parham D, Brown H, Saylors iii RL. HHV8 and pediatric pseudotumors. 1998.
    16. Wang J, Lu D, Butch AW, Rosen N, Saylors iii RL, Munshi NC. Superior response with combination of interleukin-2 (IL-2) and granulocyte macrophage colony stimulating factor (GM-CSF) gene-modified tumor vaccines in myeloma. 1998; 92:4228.
    17. Saylors iii RL, Stewart C, Wall DA, Bell B, Vietti TJ. Phase I trial of topotecan plus cyclophosphamide in children with refractory or recurrent solid tumors: A Pediatric Oncology Group Study. J Clin Oncol. 1998; 16:945-52.
    18. Kajkenova O, Saylors iii RL, Munshi NC. Liposome-mediated retroviral transduction of hematopoietic progenitor cells. 1998; 92:4623.
    19. Saylors iii RL, Wall DA. Expression of human alpha1 antitrypsin in murine hematopoietic cells in vivo after retrovirus-mediated gene transfer. Molec Genetics and Metabolism. 1998; 63:198-204.
    20. McMasters R, Saylors iii RL, Hendrix EM, Munshi N, Moyer MP, Drake RR. Ganciclovir-mediated apoptosis and lack of bystander killing in HSV-TK transduced colon cell lines. Human Gene Ther. 1998; 10:2253-61.
    21. Gill MA, Saylors iii RL, Jones SM. Immunomodulation therapy in EBV-induced lymphoproliferative disorder (LPD). 1998.
    22. Saylors iii RL, Stewart C, Wall DA, Bell B, Vietti TJ. Phase I trial of topotecan plus cyclophosphamide in children with refractory or recurrent solid tumors: A Pediatric Oncology Group Study. 1998; 16:945-52.
    23. Shirrell MA, Jones SM, James JM, Wheeler JG, Schellhase DE, Saylors iii RL, Et al. Fatal lymphoproliferative disorder five years after bone marrow transplant for severe combined immunodeficiency disease. 1997; 99:178.
    24. Drake RR, McMasters R, Krisa S, Rechtin T, Hume SD, Saylors iii RL, Et al. Metabolism and effects on HIV-1 replication of 3' -azido-2', 3' -dideoxythymidine and 2', 3' -didehydro-2',3' -dideoxythymidine in herpesvirus thymidine kinase transduced T-lymphocytes. Antiviral Res. 1997; 35:177-85.
    25. Stine KC, Saylors iii RL, Williams L, Becton DL. 2-chlorodeoxyadenosine for the treatment of refractory or recurrent Langerhan's cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol. 1997; 29:288-292.
    26. Stine KC, Saylors iii RL, Sawyer DL, Becton DL. Secondary acute myelogenous leukemia (sAML) following safe exposure to etoposide. J Clin Oncol. 1997; 15:1583-86.
    27. Drake R, McMasters R, Hendrix EM, Munshi N, Moyer MP, Saylors iii RL. Apoptosis and lack of bystander effect in ganciclovir treated HSV-TK transduced human colon cell lines. 1997.
    28. Munshi NC, Govindarajan R, Drake R, Ding LM, Saylors iii RL, Kornbluth J, Et al. Thymidine kinase gene transduced human lymphocytes can be highly purified, remain functional, and are killed efficiently with ganciclovir. Blood. 1997; 89:1334-40.
    29. Saylors iii RL, Patel R, Derrick J. Cytokine inducible reporter gene expression from the Moloney murine leukemia virus U3 promoter/enhancer. 1996; 88:136a.
    30. Munshi NC, Govindarajan R, Barlogie B, Drake R, Ding LM, Iyer R, Saylors iii RL, Et al. Thymidine kinase (TK) gene transduced human lymphocytes can be killed with ganciclovir-preclinical studies. 1995; 86:4001a.
    31. Stine KC, Williams L, Saylors iii RL, Becton DL. 2-chlorodeoxyadenosine for the treatment of refractory or recurrent Langerhan's cell histiocytosis (LCH) in pediatric patients. 1995; 86:2029a.
    32. Iyer R, Ding L, Saylors iii RL, Srivastava A, Barlogie B, Munshi N. Antisense p53 inhibits apoptosis in myeloma cells through bcl-2 overexpression. 1995; 36:A3337.
    33. Ding LM, Saylors iii RL, Munshi NC. The stromal cell as a vehicle for ex vivo gene transfer. 1995; 86:1625a.
    34. Saylors iii RL, Wall DA. Co-expression of human alpha-1-antitrypsin and a dominant selectable marker in murine bone marrow cells in vivo. Annual Southern Society for Pediatric Research. 1995.
    35. Saylors iii RL, Cohn S, Morgan E, Broderu GM. Prenatal detection of neuroblastoma by fetal ultrasonography. Am J Ped Hematol Oncol. 1994; 16:356-60.
    36. Hafenrichter DG, Ponder KP, Rettinger SD, Kennedy SC, Wu X, Saylors iii RL, Flye MW. Liver-directed gene therapy: evaluation of liver specific promoter elements. J Surg Res. 1994; 56:510-17.
    37. Fallon RJ, Danaher M, Saylors iii RL, Saxena A. Defective asialoglycoprotein receptor endocytosis mediated by tyrosine kinase inhibitors. Requirement for a tyrosine kinase in the receptor internalization signal. J Biol Chem. 1994; 269:11011-17.
    38. Rettinger S, Saylors iii RL, Flye W, Kennedy S, Wu X, Ponder KP. Long-term expression of human a-1-antitrypsin in hepatocytes after retroviral transduction. Proc Natl Acad Sci USA. 1994; 91:1460-64.
    39. Munshi NC, Ding LM, Kornbluth J, Naugler S, Saylors iii RL, Iyer R, Et al. Gene Therapy strategies for the treatment of multiple myeloma. 1994; 80:172a.
    40. Rettinger S, Ponder KP, Saylors iii RL, Kennedy S, Hafenrichter D, Flye W. In vivo transduction with retrovirus during hepatic in-flow occlusion. J Surg Res. 1993; 54:418-25.
    41. Ponder KP, Rettinger S, Saylors iii RL, Kennedy S, Flye W. Gene therapy for serum protein deficiences by using in vivo retroviral transduction. 1992; 80:367a.
    42. Brodeur GM, Azar C, Brother M, Hiemstra J, Kaufman B, Marshall H, Moley J, Nakagawara A, Saylors R, Et al. Neuroblastoma: Effect of genetic factors on prognosis and treatment. Cancer. 1992; 70:1685-94.
    43. Brodeur GM, Saylors iii RL. Neuroblastoma, retinoblastoma, and brain tumors in children. Current Opinion in Oncology. 1991; 3:485-496.
    44. Saylors iii RL, Vietti T. Rhabdomyosarcomas and related tumors in children. Pharmacologic considerations and new agent therapy. 1991.
    45. Saylors iii RL, Friedman HS, Bigner SH, Bigner DD, Vogelstein B, Brodeur GM. Infrequent p53 gene mutations in medulloblastoma. Cancer Res. 1991; 51:4721-23.
    46. Wasson JC, Saylors iii RL, Zeltzer P, Friedman HS, Bigner SH, Burger PC, Bigner DD, Look AT, Douglass EC, Brodeu GM. Oncogene amplification in pediatric brain tumors. Cancer Res. 1990; 50:2987-90.
    47. Saylors iii RL, Vietti T. Late effects of cancer treatment. Oncology. 1989; 3:85-86.
    48. Fong CT, Wasson JC, Norman D, White P, Schneider SS, Azar C, Saylors iii RL, Et al. Significance of N-myc amplification and chromosome 1p deletion in human neuroblastomas. 1989; Supplement p.58.
    Same Department Expand Description
    Search Department